ADVENT Post Approval Study

计划入组 228 人 · 首次发布于 2024 年 5 月 29 日

ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study

计划入组 356 人 · 首次发布于 2024 年 7 月 30 日

The FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial Fibrillation

计划入组 706 人 · 首次发布于 2020 年 11 月 2 日

XRN1(Accent)

antiinflammatory agent

vulnerary agent

Advent Claymore Convt Security & Income Fund

ADVENTHEALTH UNIVERSITY, INC.

United States

Adventist Healthcare, Inc.

United States

Northwest Biotherapeutics Completes Strategic Acquisition of Advent BioServices to Integrate Manufacturing Operations

Advent International Invests $175 Million in Animal Health Generics Company Felix Pharmaceuticals

Ponatinib Plus Chemotherapy Shows Promise in Philadelphia Chromosome-Positive ALL